SCHLEIFER LEONARD S 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed May 17, 2024
Insider Transaction Report
Form 4
SCHLEIFER LEONARD S
DirectorBd. Co-Chair, President & CEO
Transactions
- Sale
Common Stock
[F1][F2]2024-05-17$979.22/sh−22,687$22,215,564→ 467,020 total - Sale
Common Stock
[F1][F3]2024-05-17$980.07/sh−143$140,150→ 466,877 total
Holdings
- 157,552(indirect: 2023 GRAT)
Common Stock
- 5,932(indirect: By 401(k))
Common Stock
- 64,985(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024.
- [F2]Represents volume-weighted average price of sales of 22,687 shares of Company stock on May 17, 2024 at prices ranging from $979.00 to $979.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2024 at each separate price.
- [F3]Represents volume-weighted average price of sales of 143 shares of Company stock on May 17, 2024 at prices ranging from $980.01 to $980.20. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2024 at each separate price.
Signature
/s/**Leonard S. Schleifer|2024-05-17